Last update 01 Nov 2024
MediaPharma Srl
Last update 01 Nov 2024
Overview
Basic Info
Introduction MediaPharma Srl is a company that specializes in creating new drugs to treat cancer and other diseases that currently have no effective treatments available. The company concentrates on researching and developing humanized monoclonal antibodies, Antibody-Drug Conjugates (ADCs), and therapeutic proteins. Founded by Stefano Iacobelli in 2009, MediaPharma Srl is headquartered in Chieti, Italy. |
Tags
Neoplasms
Skin and Musculoskeletal Diseases
Digestive System Disorders
Antibody drug conjugate (ADC)
Bispecific antibody
Other diagnostic agent
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
100 Clinical Results associated with MediaPharma Srl
Login to view more data
Login to view more data
Galectin-3 binding protein stimulated IL-6 expression is impeded by antibody intervention in SARS-CoV-2 susceptible cell lines
Author: Iacobelli, Stefano ; Gentile, Roberta ; Gallo, Valentina ; Mendes-Frias, Ana ; Antonini, Giovanni ; Silvestre, Ricardo ; Iacobelli, Valentina
100 Deals associated with MediaPharma Srl
Login to view more data
100 Translational Medicine associated with MediaPharma Srl
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 26 Nov 2024
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
10
9
Other
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free